Dear Investors,

We are glad to introduce a new drug license out asset B7-H3×CD3 BsAb for solid tumors. The asset is looking for out-licensing and co-development.

Here are the details, please get in touch with us if you are interested.

★ Asset type: B7-H3×CD3 BsAb 

★ Indications: Solid tumor

★ Modality: BsAb

★ Research: IND

★ Demands: License-out or co-development

▶ Novel anti-tumor strategy

Picarda, Elodie et al. “Molecular Pathways: Targeting B7-H3 (CD276) for Human Cancer Immunotherapy.” Clinical cancer research: an official journal of the American Association for Cancer Research vol. 22,14 (2016): 3425-3431.

Data access from TCGA.

• B7-H3 is highly expressed in many different types of solid tumor, but is lowly expressed in normal tissue. B7-H3 plays an important role in inhibiting T-cell function and promoting cancer progression and invasion. B7-H3 high expression remains poor prognosis and patient survival.
• B7-H3×CD3 bispecific antibody can mediate cytotoxic activities against B7-H3-positive tumor cells by improving T cell activation.

▶ Asset binds to CD3 and B7-H3 antigen simultaneously.

▶ Excellent anti-tumor efficacy in vitro and in vivo.

• The asset redirected T-Cell activation to kill B7-H3⁺ AsPC-1 (pancreatic cancer) and NCI-N87 (gastric cancer).
• The asset suppresses tumor growth in NCI-N87 xenograft model.

▶ Good safety in preclinical study.

• The Asset shows a positive safety profile in toxicity studies with Cynomolgus Monkeys.

✓There were no animal death and no adverse effects

✓No liver impairment was observed, compared to other BsAb target CD3 and B7-H3.

✓The asset induced very low cytokine release(IL-2, IL-6, TNF-α, IFN-γ) in Cynomolgus monkeys.

• The asset is well-tolerated in Cyno monkeys and the NOAEL is the highest dose tested at 3.6 mg/kg once weekly for 4 consecutive weeks (5 doses in total).

▶ Innovative BsAb development platform

• After reasonable design of heavy and light chains, the mismatch probability of asset is greatly reduced.
• Creative CMC, which greatly simplified the production and purification process, through one step affinity chromatography the purity can be higher than 95%.
• The platform brings a much lower cost of production.

▶ IND stage

▶ Good anti-tumor efficacy in the animal model

▶ Good safety

▶ Innovative CMC that lowers the cost of production

Glad to have you aboard. We encourage you to reply this email directly if you have any license in or out requests.

Best regards

The bioSeedin Team

www.bioseedin.com

license@bioseedin.com

Follow us on social media